IL-6 biomarker breakthrough for early sepsis detection
New research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
New research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
Two prominent European biospecimen and life sciences companies have combined to strengthen research capabilities across Europe and North America, marking significant expansion in biospecimen services and stem cell research sectors.
Cellular Origins, a TTP company specialising in cell and gene therapy (CGT) manufacturing solutions, has announced the acquisition of the Autologous Cell Therapy Industrial Automation (ACTIA) Platform intellectual property. The acquisition is set to augment the company’s existing Constellation™ platform, which was launched in May 2023.
A unique portfolio of neurobiomarker tests The testing landscape for neurological diseases has expanded rapidly in recent years due to the characterisation of many novel biomarkers. With over 15 years of experience in neurological analytics, EUROIMMUN offers an unparalleled portfolio of assays for determination of more than 80 neurobiomarkers in autoimmune diseases, neurological infections and […]
In a significant move for gene therapy research, Annogen has announced a collaboration with Orchard Therapeutics to identify immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programmes. This partnership aims to advance the development of more targeted and potentially safer gene therapies for central nervous system (CNS) disorders.
Researchers at Moffitt Cancer Center have developed a novel method for the scalable synthesis of withanolides, a class of naturally occurring compounds with significant potential in cancer treatment. This groundbreaking approach, published in Science Advances [1], could revolutionise cancer research by providing a reliable and efficient means of producing these vital compounds in large quantities.
Scientists at King’s College London have developed a rapid method for creating cyclic peptides, potentially accelerating the production of new antibiotics to combat antimicrobial resistance (AMR). The research, published in the Journal of the American Chemical Society [1], demonstrates a technique that reduces synthesis time from hours or days to mere minutes.
The association of epigenetic changes with disease pathogenesis is the subject of much study. CLI caught up with Dr Kathleen Barnes (Oxford Nanopore Technologies) to find out more about how DNA methylation is linked to disease as well as developments in methods of DNA methylation analysis for improving disease diagnosis, prognostic stratification and therapy.
By Dr Stephen Langabeer The myeloproliferative neoplasms of polycythemia vera, essential thrombocythemia and primary myelofibrosis are clonal hematopoietic disorders characterized by an over-production of mature blood cells. Molecular evaluation is a key component of differentiating malignancy from a host of reactive causes with mutations in JAK2, CALR and MPL genes present in the majority of […]
Produced using a patented dry-spinning technology – CollaFibR from AMSBIO is a highly consistent collagen fibre matrix that closely mimics the biomechanical and biochemical properties of natural collagen scaffolds, offering an accurate representation of in-vivo conditions.
February | March 2025
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy